Low-dose rosuvastatin improves arterial stiffness in high-risk Japanese patients with dyslipdemia in a primary prevention group: A comparison with fluvastatin

Circulation Journal

Volumn 75, Issue 11, 2011, Pages 2660-2667

  Hongo, Minoru ^a   Kumazaki, Setsuo ^b   Izawa, Atsushi ^b   Hidaka, Hiroya ^a   Tomita, Takeshi ^b   Yazaki, Yoshikazu ^c   Kinoshita, Osamu ^d   Ikeda, Uichi ^b  

^a SHINSHU UNIVERSITY   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Matsumoto Hospital   (Japan)

^d Azumino Red Cross Hospital   (Japan)

Author keywords

Arterial stiffness; Dyslipidemia; Fluvastatin; High risk patients; Rosuvastatin

Indexed keywords

C REACTIVE PROTEIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANKLE BRACHIAL INDEX; ANTIINFLAMMATORY ACTIVITY; ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; JAPANESE; LIPID BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIMARY PREVENTION; PROSPECTIVE STUDY; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FATTY ACIDS, MONOUNSATURATED; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; JAPAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINES; RISK FACTORS; SULFONAMIDES; TIME FACTORS; VASCULAR STIFFNESS;

EID: 80054902423     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0497     Document Type: Article

References (40)

1. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscle Thromb Vasc Biol 2005; 25: 932-943.
2. Cohn JN. Arterial stiffness, vascular disease, and risk of cardiovascular events. Circulation 2006; 113: 601-603.
3. Tomiyama H, Yamashina A. Non-invasive vascular function tests: Their pathophysiological background and clinical application. Circ J 2010; 74: 24-33.
4. Pannier B, Guerin AP, Marchais SJ, Safar ME, London GM. Stiffness of capacitative and conduit arteries: Prognostic significance for endstage renal disease patients. Hypertension 2005; 45: 592-596.
5. Boutouyrie P, Isabelle A, Asmar R, Gatier I, Benetos A, Lacolley P, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: A longitudinal study. Hypertension 2002; 39: 10-15.
6. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: An integrated index of vascular function? Circulation 2002; 106: 2085-2090.
7. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness. J Am Coll Cardiol 2010; 55: 1318-1327.
8. Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencia MJ, Hamburg NM, et al. Arterial stiffness and cardiovascular events: The Framingham Heart Study. Circulation 2010; 121: 505-511.
9. Inoue N, Maeda R, Kawakami H, Shokawa T, Yamamoto H, Ito C, et al. Aortic pulse wave velocity predicts cardiovascular mortality in middle-aged and elderly Japanese men. Circ J 2009; 73: 549-553.
10. Hongo M, Tsutsui H, Mawatari E, Hidaka H, Kumazaki S, Yazaki Y, et al. Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia: A 5-year follow-up study. Circ J 2008; 72: 722-728.
11. Miyashita Y, Endo K, Saiki A, Ban N, Yamaguchi T, Kawana H, et al. Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb 2009; 16: 539-545.
12. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases. 2007; 1-98 (in Japanese).
13. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002; 25: 359-364.
14. Sugawara J, Hayashi K, Yokoi T, Cortez-Cooper MY, DeVan AE, Anton MA, et al. Brachial-ankle pulse wave velocity: An index of central arterial stiffness? J Hum Hypertens 2005; 19: 401-406.
15. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al; for the ASTERIOD Investigators. Effect of very highintensity statin therapy on regression of coronary atherosclerosis: The ASTERIOD Trial. JAMA 2006; 295: 1556-1565.
16. Schwarz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndrome: The MIRACL study: A randomized controlled trial. JAMA 2001; 285: 1711-1718.
17. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48: 438-445.
18. Gibson CM, Pride YB, Hochberg CP, Sloan S, Sabatine MS, Cannon CP; for the TIMI Study Group. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. J Am Coll Cardiol 2009; 54: 2290-2295.
19. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, et al. for the MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet 2006; 368: 1155-1163.
20. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, et al. Early statin treatment in patients with acute coronary syndrome: Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: The ESTABLISH Study. Circulation 2004; 110: 1061-1068.
21. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, et al; for the Japan-ACS Investigators. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: A multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome] Study). J Am Coll Cardiol 2009; 54: 293-302.
22. Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, et al. for the COSMOS Investigators: Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: Multicenter coronary atheroscrelosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J 2009; 73: 2110-2117.
23. Saku K, Zhang B, Noda K; on behalf of the PATROL Trial Investigators. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (Quantity and Quality of LDL): The PATROL Trial. Circ J 2011; 75: 1493-1505.
24. Dohi T, Miyauchi K, Okazaki S, Yokoyama T, Yanagisawa N, Tamura H, et al. Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): A follow-up study. Atherosclerosis 2010; 210: 497-502.
25. Kojima S, Sakamoto T, Ogawa H, Kitagawa A, Matsui K, Shimomura H, et al; on behalf of the Multicenter Study for Aggressive Lipidlowering Strategy by HMG-CoA Reductase Inhibitors (MUSASHI) Investigators. Standard-dose statin therapy provides incremental clinical benefits in normocholesterolemic diabetic patients. Circ J 2010; 74: 779-785.
26. Miyauchi K, Daida H. Clinical significance of intensive lipid-lowering therapy using statins in patients with coronary artery disease: LDL-cholesterol: The lower, the better; Is it true for Asians? (Pro) Circ J 2010; 74: 1718-1730.
27. Sakamoto T, Ogawa H. "Just make it lower" is an alternative strategy of lipid-lowering therapy with statins in Japanese patients: The lower, the better; Is it true for Asians? (Con) Circ J 2010; 74: 1731-1741.
28. Tanaka H, Munakata M, Kawano Y, Ohishi M, Shoji T, Sugawara J, et al. Comparison between carotid-femoral and brachial-ankle pulse wave velocity as measures of arterial stiffness. J Hypertens 2009; 27: 2022-2027.
29. Tsuchikura S, Shoji T, Kimoto E, Shinihara K, Hatsuda S, Koyama H, et al. Brachial-ankle pulse wave velocity as an index of central arterial stiffness. J Atheroscler Thromb 2010; 17: 658-665.
30. Yamashina A, Tomiyama H, Arai T, Hirose KI, Koji Y, Hirayama Y, et al. Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens Res 2003; 26: 615-622.
31. Munakata M, Ito N, Nunokawa T, Yoshinaga K. Utility of automated brachial ankle pulse wave velocity measurements in hypertensive patients. Am J Hypertens 2003; 16: 653-657.
32. Tomiyama H, Koji Y, Yambe M, Shiina K, Motobe K, Yamada J, et al. Brachial-ankle pulse wave velocity is a simple and independent predictor of prognosis in patients with acute coronary syndrome. Circ J 2005; 69: 815-822.
33. Matsumoto I, Miyake Y, Mizukawa M, Takagi Y. Impact of lowdensity lipoprotein cholesterol/high-density lipoprotein cholesterol ratio on long-term outcome in patients undergoing percutaneous coronary intervention. Circ J 2011; 75: 905-910.
34. Yokokawa H, Yasumura S, Tanno K, Ohsawa M, Onoda T, Itai K, et al. Serum low-density lipoprotein to high-density lipoprotein ratio as a predictor of future acute myocardial infarction among men in a 2.7-year cohort study of a Japanese northern rural population. J Atheroscler Thromb 2011; 18: 89-98.
35. Otagiri K, Tsutsui H, Kumazaki S, Miyashita Y, Aizawa K, Koshikawa M, et al. Early intervention with rosuvastatin decreases the lipid components of the plaque in acute coronary syndrome: Analysis using integrated backscatter IVUS (ELAN Study). Circ J 2011; 75: 633-641.
36. Kostapanos MS, Milionis HJ, Elisaf MS. An overview of the extralipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther 2008; 13: 157-174.
37. Liberropoulos EN, Daskalopoulou SS, Mikhailidis DP, Wierzbicki AS, Elisaf MS. A review of the lipid-related effects of fluvastatin. Curr Med Res Opin 2005; 21: 231-243.
38. Williams B, Lacy PS, Cruickshank JK, Collier D, Hughes AD, Stanton A, et al; for the CAFE and ASCOT Investigators: Impact of statin therapy on central aortic pressures and hemodynamics: Principal results of the Conduit Artery Function Evaluation-Lipid Lowering Arm (CAFE-LLA) Study. Circulation 2009; 119: 53-61.
39. Lee HY, Oh BH. Aging and arterial stiffness. Circ J 2010; 74: 2257-2262.
40. Yambe T, Yoshizawa M, Saijyo Y, Yamaguchi T, Shibata M, Konno S, et al. Brachio-ankle pulse wave velocity and cardio-ankle vascular index (CAVI). Biomed Pharmacother 2004; 58(Suppl): S95-S98.